AI στο Pharma

Define the intended use, population, endpoint, and decision boundary. A model prioritizing compounds for laboratory study differs from one used to inform a clinical submission. Preserve the distinction between exploratory hypotheses and evidence used to support safety or effectiveness. Use documented data provenance, quality controls, and appropriate validation. Check batch effects, missing measurements, site differences, and whether the outcome label is a meaningful proxy. For time-dependent or prospective decisions, use evaluation data that respects when information becomes available. FDA and EMA guiding principles emphasize human-centered design, risk-based approaches, context of use, multidisciplinary expertise, data governance, performance assessment, and lifecycle management. Treat these as a framework for evidence and accountability, not as a blanket approval of a model. Retain versioned protocols, model outputs, and review decisions. Monitor performance after deployment and define how a change in data, assay, or model triggers reassessment.